Business Overview: Castle Biosciences, Inc. (NASDAQ: CSTL)

Executive Summary

Castle Biosciences, Inc. is a molecular diagnostics company, founded in 2008, that develops and commercializes multi-analyte gene expression profile (GEP) and spatialomics tests designed to personalize treatment decisions across dermatologic cancers, gastrointestinal disease, and atopic dermatitis. The company's core product portfolio includes DecisionDx-Melanoma (risk stratification for invasive cutaneous melanoma, addressing an estimated $540 million total addressable market), DecisionDx-SCC (a gene expression profile test for high-risk squamous cell carcinoma, ~$820 million TAM), MyPath Melanoma (a diagnostic aid for difficult-to-diagnose melanocytic lesions, ~$600 million TAM), TissueCypher (a spatialomics test predicting Barrett's esophagus progression to esophageal cancer, ~$1 billion TAM), DecisionDx-UM (risk stratification for uveal melanoma), and the newly launched AdvanceAD-Tx (a test guiding treatment selection for moderate-to-severe atopic dermatitis, addressing a massive estimated $33 billion TAM given the prevalence of the underlying condition).

The single most decision-relevant fact for investors is Castle Biosciences' accelerating growth and improving profitability trajectory, driven by both volume growth and portfolio expansion into adjacent high-TAM categories. The company delivered 105,053 test reports in 2025 (up from 96,071 in 2024), generating $344.2 million in net revenue, and second-quarter 2026 revenue reached $103.5 million (up 20% year-over-year), meaningfully exceeding analyst expectations and prompting management to raise full-year 2026 guidance to $365–375 million while projecting positive adjusted EBITDA for full-year 2026 and both Q3 and Q4. This momentum arrives even as the company navigates a significant reimbursement setback — DecisionDx-SCC lost Medicare coverage in April 2025 — underscoring that payor and reimbursement dynamics remain the central swing factor for this business model, more so than clinical validation or physician adoption, both of which appear robust.

Trading with a market capitalization of approximately $1.08 billion (up 53.9% recently) and a trailing-twelve-month revenue base of $357.3 million growing at over 3% year-over-year (with the growth rate reaccelerating sharply in recent quarters), Castle Biosciences remains GAAP unprofitable (a net loss of $19.4 million, EPS of $(0.65)) but is approaching an inflection point toward sustained positive adjusted EBITDA. The company's approval for a dual listing on Nasdaq Texas, a new 55,000-square-foot Arizona laboratory facility, and a nine-analyst "Strong Buy" consensus with a $44 price target (implying roughly 25% upside) collectively signal a company in an active investment and expansion phase, betting that its proprietary algorithm-driven diagnostic platform can continue capturing share across an expanding set of high-value dermatologic, gastrointestinal, and now allergy/immunology-adjacent markets.

1. Core Business Model & How They Work

Castle Biosciences generates revenue by performing proprietary, laboratory-developed molecular diagnostic tests on patient tissue samples and billing healthcare payors (Medicare, commercial insurers) and, in some cases, patients directly. Key operational drivers include:

1. Test volume growth — the number of test reports delivered (105,053 in 2025) is the primary top-line driver, reflecting both physician adoption of existing tests and expansion into new clinical indications.
2. Multi-analyte algorithmic testing — each test combines gene expression or spatial biomarker data with proprietary algorithms to generate a risk score or treatment-guidance output, differentiating from single-marker or purely histopathological approaches.
3. Payor reimbursement and coverage — securing and maintaining Medicare and commercial payor coverage is critical to revenue realization per test, as illustrated by the material impact of DecisionDx-SCC's April 2025 Medicare coverage loss.
4. Clinical validation and publication strategy — ongoing peer-reviewed studies validating test performance (including for TissueCypher and DecisionDx-SCC) support both physician adoption and payor coverage decisions.
5. Portfolio expansion into adjacent high-TAM markets — moving beyond dermatologic oncology into gastroenterology (TissueCypher) and now immunology/dermatology treatment-guidance (AdvanceAD-Tx) diversifies revenue and taps substantially larger addressable markets.
6. Laboratory capacity investment — the new 55,000-square-foot Arizona facility expands testing capacity to support continued volume growth across the expanding test menu.

2. Business Segments

Castle Biosciences operates as a single reportable segment (molecular diagnostics) organized around three clinical franchises:

• Dermatology: DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, and the newly launched AdvanceAD-Tx for atopic dermatitis — historically the largest revenue contributor.
• Gastroenterology: TissueCypher for Barrett's esophagus progression risk.
• Ophthalmology: DecisionDx-UM for uveal melanoma risk stratification — the smallest franchise by addressable market.

3. Product Portfolio

4. Competitive Landscape

Castle Biosciences' primary competition is not other commercial diagnostic companies but rather traditional clinical and pathology staging criteria (AJCC staging, Breslow depth, and standard histopathology) that clinicians have long relied upon to make treatment decisions absent a molecular test. Where commercial competition does exist, it is most direct in the DecisionDx-UM ocular melanoma category, where Castle competes against Labcorp subsidiaries and academic reference laboratories. The company's competitive strategy centers on building a large base of peer-reviewed clinical validation data and demonstrating clear reimbursement value to differentiate its algorithmic tests from both legacy staging methods and any emerging competitive molecular tests, particularly as AdvanceAD-Tx enters the far larger and more competitive dermatology/immunology treatment-selection market.

Key Competitors:

• Traditional AJCC clinical/pathological staging (the primary "competitor" in oncology dermatology)
• Labcorp (ocular melanoma testing via subsidiaries)
• Academic/institutional reference laboratories
• Myriad Genetics (adjacent molecular diagnostics/oncology testing)
• Emerging biomarker-based diagnostics entrants in atopic dermatitis/immunology as AdvanceAD-Tx scales

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Large, growing library of peer-reviewed clinical validation studies across multiple test lines, raising the evidentiary bar for new entrants.
• Proprietary, algorithm-driven multi-analyte tests that are difficult to replicate without equivalent clinical outcome datasets.
• Diversified, high-TAM product portfolio spanning dermatology, gastroenterology, and now immunology/allergy, reducing dependence on any single reimbursement decision.
• Demonstrated payor relationships and reimbursement track record across Medicare and major commercial insurers for its established tests.
• New Arizona laboratory facility and Nasdaq Texas dual listing reflect expanding operational and capital markets infrastructure supporting continued scale-up.

Strategic Risks & Vulnerabilities

1. High revenue concentration in payor reimbursement decisions — 44% of 2025 revenue from Medicare and 16% from a single commercial payor — creates material earnings sensitivity to any coverage changes.
2. DecisionDx-SCC's loss of Medicare coverage in April 2025 demonstrates that even established, clinically validated tests face real reimbursement risk.
3. Ongoing regulatory uncertainty regarding FDA oversight of laboratory-developed tests (LDTs) could materially change the compliance and commercialization pathway for the entire test portfolio.
4. Dependence on sole suppliers for critical reagents and laboratory equipment introduces supply chain risk to testing capacity.
5. AdvanceAD-Tx, while addressing a very large TAM, is newly launched and unproven at commercial scale, with adoption and reimbursement pathways still being established.
6. Continued GAAP net losses ($19.4 million TTM) mean the path to sustained profitability, while improving, is not yet fully established.
7. Competitive and reimbursement dynamics in the much larger dermatology/immunology market (AdvanceAD-Tx) are less proven than in Castle's historical oncology niches.

6. Financial Overview

7. Summary Conclusion

Castle Biosciences has built a genuinely differentiated, clinically validated molecular diagnostics franchise spanning dermatologic oncology, gastroenterology, and now immunology/allergy, with accelerating revenue growth (Q2 2026 up 20% year-over-year) and a credible path to sustained positive adjusted EBITDA in 2026. The company's core investment risk is not clinical or competitive but regulatory and payor-driven: the DecisionDx-SCC Medicare coverage loss is a clear reminder that reimbursement decisions, not physician demand, remain the binding constraint on revenue realization for laboratory-developed tests, and the ongoing uncertainty around FDA regulation of LDTs adds a further overhang. For investors comfortable underwriting execution risk on the newly launched, enormous-TAM AdvanceAD-Tx opportunity alongside reimbursement risk in the core oncology franchise, Castle Biosciences offers a credible, growing, and increasingly profitable way to invest in precision-medicine diagnostics.